Free Ivory Coast: 2016

Wednesday, October 12, 2016

MetroGel

See also: Generic MetroCream, Generic MetroGel-Vaginal, Generic MetroLotion

MetroGel is a brand name of metronidazole topical, approved by the FDA in the following formulation(s):

METROGEL (metronidazole - gel; topical)

Manufacturer: GALDERMA LABS LP

Approval date: November 22, 1988

Strength(s): 0.75% ^[RLD]^[AB]

Manufacturer: GALDERMA LABS LP

Approval date: June 30, 2005

Strength(s): 1% ^[RLD]^[AB]

Has a generic version of MetroGel been approved?

A generic version of MetroGel has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to MetroGel and have been approved by the FDA:

metronidazole gel; topical

Manufacturer: FOUGERA PHARMS

Approval date: June 6, 2006

Strength(s): 0.75% ^[AB]

Manufacturer: G AND W LABS INC

Approval date: January 19, 2011

Strength(s): 0.75% ^[AB]

Manufacturer: TARO

Approval date: July 18, 2006

Strength(s): 0.75% ^[AB]

Manufacturer: TOLMAR

Approval date: July 13, 2006

Strength(s): 0.75% ^[AB]

Manufacturer: TOLMAR

Approval date: July 22, 2011

Strength(s): 1% ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of MetroGel. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Aqueous compositions containing metronidazole
Patent 6,881,726
Issued: April 19, 2005
Inventor(s): Chang; Yunik & Dow; Gordon J.
Assignee(s): Dow Pharmaceutical Sciences
An aqueous solution of metronidazole in which the concentration of metronidazole is higher than 0.75%. The solution contains a combination of solubility-enhancing agents, one of which is a cyclodextrin such as beta-cyclodextrin and the second is a compound other than a cyclodextrin. Methods of manufacture and therapeutic use of the solution are disclosed.
Patent expiration dates:
- February 21, 2022
  ✓
  Patent use: ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA
  ✓
  Drug product

Aqueous compositions containing metronidazole
Patent 7,348,317
Issued: March 25, 2008
Inventor(s): Chang; Yunik & Dow; Gordon J.
Assignee(s): Dow Pharmaceutical Sciences
An aqueous solution of metronidazole in which the concentration of metronidazole is higher than 0.75%. The solution contains a combination of solubility-enhancing agents, one of which is a cyclodextrin such as beta-cyclodextrin and the second is niacin or niacinamide. Methods of manufacture and therapeutic use of the solution are disclosed.
Patent expiration dates:
- February 21, 2022
  ✓
  Patent use: ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA
  ✓
  Drug product

Has a generic version of Mifeprex been approved?

No. There is currently no therapeutically equivalent version of Mifeprex available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Mifeprex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Mifeprex.

Has a generic version of DuoDote been approved?

No. There is currently no therapeutically equivalent version of DuoDote available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of DuoDote. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with DuoDote.

Has a generic version of Capastat Sulfate been approved?

No. There is currently no therapeutically equivalent version of Capastat Sulfate available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Capastat Sulfate. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Capastat Sulfate.

Has a generic version of Carafate been approved?

Yes. The following products are equivalent to Carafate:

sucralfate tablet; oral

Manufacturer: NOSTRUM LABS

Approval date: June 8, 1998

Strength(s): 1GM ^[AB]

Manufacturer: TEVA

Approval date: March 29, 1996

Strength(s): 1GM ^[AB]

Note: No generic formulation of the following product is available.

sucralfate - suspension; oral

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Carafate. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Carafate.

Has a generic version of Somavert been approved?

No. There is currently no therapeutically equivalent version of Somavert available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Somavert. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Growth hormone antagonists
Patent 5,350,836
Issued: September 27, 1994
Inventor(s): Kopchick; John J. & Chen; Wen Y.
Assignee(s): Ohio University
The present invention relates to antagonists of vertebrate growth hormones obtained by mutation of the third alpha helix of such proteins (especially bovine or human GHs). These mutants have growth inhibitory or other GH-antagonizing effects. These novel hormones may be administered exogenously to animals, or transgenic animals may be made that express the antagonist. Animals have been made which exhibited a reduced growth phenotype.
Patent expiration dates:
- September 27, 2011
  ✓
  Patent use: ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE

Growth hormone antagonists
Patent 5,681,809
Issued: October 28, 1997
Inventor(s): Kopchick; John J. & Chen; Wen Y.
Assignee(s): Ohio University
The present invention relates to antagonists of vertebrate growth hormones obtained by mutation of the third alpha helix of such proteins (especially bovine or human GHs). These mutants have growth inhibitory or other GH-antagonizing effects. These novel hormones may be administered exogenously to animals, or transgenic animals may be made that express the antagonist. Animals have been made which exhibited a reduced growth phenotype.
Patent expiration dates:
- September 27, 2011
  ✓
  Patent use: ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE

Human growth hormone variants
Patent 5,849,535
Issued: December 15, 1998
Inventor(s): Cunningham; Brian C. & Lowman; Henry B. & Wells; James A. & Clark; Ross G. & Olson; Kenneth & Fuh; Germaine G.
Assignee(s): Genentech, Inc.
Human growth hormone variants, DNA encoding the variants, vectors, host cells, pegylated forms of the variants, as well as methods of making the variants are disclosed.
Patent expiration dates:
- March 25, 2017
  ✓
  Drug substance

Growth hormone receptor antagonists and methods of reducing growth hormone activity in a mammal
Patent 5,958,879
Issued: September 28, 1999
Inventor(s): Kopchick; John J. & Chen; Wen Y.
Assignee(s): Ohio University/Edison Biotechnology Institute
The present invention relates to antagonists of vertebrate growth hormones obtained by mutation of the third alpha helix of such proteins (especially bovine or human GHs). These mutants have growth-inhibitory or other GH-antagonizing effects. These novel hormones may be administered exogenously to mammals. The antagonists may be used to reduce the activity of growth hormone in a mammal, especially one suffering from diabetes, diabetic retinopathy, diabetic nephropathy, a growth hormone secreting tumor, acromegaly, or gigantism.
Patent expiration dates:
- September 27, 2011
  ✓
  Patent use: ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE

Method for inhibiting growth hormone action
Patent 6,057,292
Issued: May 2, 2000
Inventor(s): Cunningham; Brian C. & Lowman; Henry B. & Wells; James A. & Clark; Ross G. & Olson; Kenneth & Fuh; Germaine G.
Assignee(s): Genentech, Inc.
Human growth hormone variants are disclosed having enhanced affinity for the growth hormone receptor. Also disclosed are human growth hormone variants conjugated to one or more chemical groups, such as poly(ethylene glycol), which is believed to prolong the in vivo half-life of the variants.
Patent expiration dates:
- September 21, 2015
  ✓
  Patent use: ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE

Methods for treating acromegaly and giantism with growth hormone antagonists
Patent 6,583,115
Issued: June 24, 2003
Inventor(s): John J.; Kopchick & Wen Y.; Chen
Assignee(s): Ohio University/Edison Biotechnology Institute
The present invention relates to antagonists of vertebrate growth hormones obtained by mutation of the third alpha helix of such proteins (especially bovine or human GHs). These mutants-have growth-inhibitory or other GH-antagonizing effects. These novel hormones may be administered exogenously to animals, or transgenic animals may be made that express the antagonist. Animals have been made which exhibited a reduced growth phenotype. The invention also describes methods of treating acromegaly, gigantism, cancer, diabetes, vascular eye diseases (diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, retinopathy of sickle-cell anemia, etc.) as well as nephropathy and other diseases, by administering an effective amount of a growth hormone antagonist. The invention also provides pharmaceutical formulations comprising one or more growth hormone antagonists.
Patent expiration dates:
- September 27, 2011
  ✓
  Patent use: ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE

Has a generic version of Brevibloc been approved?

A generic version of Brevibloc has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Brevibloc and have been approved by the FDA:

esmolol hydrochloride injectable; injection

Manufacturer: APP PHARMS

Approval date: May 2, 2005

Strength(s): 10MG/ML ^[AP]

Manufacturer: BEDFORD LABS

Approval date: August 10, 2004

Strength(s): 10MG/ML ^[AP]

Manufacturer: BIONICHE PHARMA

Approval date: May 2, 2005

Strength(s): 10MG/ML ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Brevibloc. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Ready-to-use esmolol solution
Patent 6,310,094
Issued: October 30, 2001
Inventor(s): Liu; Jie & Pejaver; Satish K. & Owoo; George
Assignee(s): Baxter International Inc.
A ready-to-use injectable, aqueous pharmaceutical composition for the treatment of cardiac conditions, comprising methyl-3-[4-(2-hydroxy-3-isopropylamino) propoxy] phenylpropionate hydrochloride (esmolol hydrochloride), a buffering agent and an osmotic-adjusting agent, as well as a method for its manufacture in a container, is disclosed.
Patent expiration dates:
- January 12, 2021
- July 12, 2021
  ✓
  Pediatric exclusivity

Esmolol formulation
Patent 6,528,540
Issued: March 4, 2003
Inventor(s): Jie; Liu & Satish K.; Pejaver & George; Owoo
Assignee(s): Baxter International Inc.
An aqueous, sterile pharmaceutical composition suitable for parenteral administration for the treatment of cardiac conditions, comprising methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate hydrochloride (esmolol hydrochloride), a buffering agent and an osmotic-adjusting agent, as well as a method for its manufacture, are disclosed.
Patent expiration dates:
- January 12, 2021
- July 12, 2021
  ✓
  Pediatric exclusivity

Has a generic version of Cipro HC been approved?

No. There is currently no therapeutically equivalent version of Cipro HC available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cipro HC. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Method of treating otitis with ciprofloxacin-hydrocortisone suspension
Patent 5,843,930
Issued: December 1, 1998
Inventor(s): Purwar; Shivaji & Goldman; David
Assignee(s): Bayer Corporation
The invention is directed to a method of treating otitis which comprises introducing an antibacterially-effective amount of a composition comprising a non-ototoxic, topical, otic pharmaceutic composition comprising (a) ciprofloxacin in aqueous solution in an amount effective for antibacterial action; (b) a non-ionic viscosity augmenter unaffected by pH and ionic level, said viscosity augmenter being present in an amount effective for augmenting viscosity of the composition to a viscosity greater than that of water, said viscosity augmenter being at least 85% hydrolyzed polyvinyl alcohol; (c) a non-ototoxic preservative present in an amount effective for antibacterial action, the preservative being benzyl alcohol; (d) water sufficient to produce an aqueous composition; (e) hydrocortisone in aqueous suspension in an amount effective for anti-inflammatory action; (f) lecithin in an amount effective for enhancing suspension of other constituents in the composition; and (g) polysorbate ranging from polysorbate 20 to 80 in an amount effective for spreading the preparation on a hydrophobic skin surface to the site of infection or inflammation.
Patent expiration dates:
- June 6, 2015
  ✓
  Patent use: METHOD OF TREATING OTITIS

Ciprofloxacin-hydrocortisone suspension
Patent 5,965,549
Issued: October 12, 1999
Inventor(s): Purwar; Shivaji & Goldman; David
Assignee(s): Bayer Aktiengesellschaft
The invention is directed to an aqueous non-ototoxic, topical, otic pharmaceutical composition of matter for treating a mammal consisting essentially of: ciprofloxacin or a pharmaceutically acceptable salt thereof in aqueous solution in an amount effective for antibacterial action; hydrocortisone or a pharmaceutically acceptable salt thereof in an amount effective as an anti-inflammatory agent; polyvinyl alcohol at least about 85% hydrolyzed in an amount effective to suspend the hydrocortisone in solution; water sufficient to produce an aqueous composition; benzyl alcohol in an amount effective for antibacterial action; lecithin in an amount effective for enhancing suspension of other constituents in the composition; and polysorbate ranging from polysorbate 20 to 80 in an amount effective for spreading the preparation on a hydrophobic skin surface to the site of infection or inflammation.
Patent expiration dates:
- June 6, 2015
  ✓
  Drug product

Has a generic version of Avodart been approved?

A generic version of Avodart has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Avodart and have been approved by the FDA:

dutasteride capsule; oral

Manufacturer: BARR

Approval date: December 21, 2010

Strength(s): 0.5MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Avodart. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Androstenone derivative
Patent 5,565,467
Issued: October 15, 1996
Inventor(s): Batchelor; Kenneth W. & Frye; Stephen V. & Dorsey, Jr.; George F. & Mook, Jr.; Robert A.
Assignee(s): Glaxo Wellcome Inc.
The present invention relates to the compound of formula (I), ##STR1## also known as 17.beta.-N-(2,5-bis(Trifluoromethyl))phenylcarbamoyl-4-aza-5.alpha.-andros t-1-en-3-one, solvates thereof, its preparation, intermediates used in its preparation, pharmaceutical formulations thereof and its use in the treatment of androgen responsive and mediated diseases.
Patent expiration dates:
- November 20, 2015
  ✓
  Drug substance
  ✓
  Drug product

Androstenone derivative
Patent 5,846,976
Issued: December 8, 1998
Inventor(s): Batchelor; Kenneth William & Frye; Stephen Vernon & Dorsey, Jr.; George F. & Mook, Jr.; Robert A.
Assignee(s): Glaxo Wellcome Inc.
The present invention relates to the compound of formula (I), ##STR1## also known as 17.beta.-N-(2,5-bis(Trifluoromethyl))phenylcarbamoyl-4-aza-5.alpha.-andros t-1-en-3-one, solvates thereof, its preparation, intermediates used in its preparation, pharmaceutical formulations thereof and its use in the treatment of androgen responsive and mediated diseases.
Patent expiration dates:
- September 17, 2013
  ✓
  Patent use: METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY

Androstenones
Patent 5,998,427
Issued: December 7, 1999
Inventor(s): Batchelor; Kenneth William & Frye; Stephen Vernon
Assignee(s): Glaxo Wellcome Inc.
The present invention relates to compounds of formula (I), wherein carbons 1 and 2 are joined by either a single or a double bond; R.sup.1 is hydrogen or methyl; R.sup.2 is hydrogen or methyl; R.sup.3 is (B) wherein X, R.sup.6, R.sup.7 and R.sup.8 are various groups, and pharmaceutically acceptable solvates thereof and their use in the treatment of androgen responsive and mediated diseases. ##STR1##
Patent expiration dates:
- September 17, 2013
  ✓
  Patent use: METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA
  ✓
  Drug substance
  ✓
  Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

Exclusivity expiration dates:
- June 19, 2011 - USE OF DUTASTERIDE IN COMBINATION WITH TAMSULOSIN FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH)

Has a generic version of Robinul been approved?

A generic version of Robinul has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Robinul and have been approved by the FDA:

glycopyrrolate injectable; injection

Manufacturer: HIKMA FARMACEUTICA

Approval date: September 21, 2011

Strength(s): 0.2MG/ML ^[AP]

Manufacturer: LUITPOLD

Approval date: July 23, 1986

Strength(s): 0.2MG/ML ^[AP]

glycopyrrolate tablet; oral

Manufacturer: BOCA PHARMA

Approval date: October 19, 2011

Strength(s): 1MG ^[AA]

Manufacturer: COREPHARMA

Approval date: December 22, 2004

Strength(s): 1MG ^[AA]

Manufacturer: DR REDDYS LABS LTD

Approval date: March 21, 2008

Strength(s): 1MG ^[AA]

Manufacturer: PAR PHARM

Approval date: August 31, 2006

Strength(s): 1MG ^[AA]

Manufacturer: RANBAXY

Approval date: August 18, 2009

Strength(s): 1MG ^[AA]

Manufacturer: VINTAGE

Approval date: December 29, 2008

Strength(s): 1MG ^[AA]

Manufacturer: WEST WARD

Approval date: March 5, 2009

Strength(s): 1MG ^[AA]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Robinul. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Method for increasing the bioavailability of glycopyrrolate
Patent 7,091,236
Issued: August 15, 2006
Inventor(s): Roberts; Alan & Venkataraman; Bala
Assignee(s): Sciele Pharma, Inc.
The invention relates to a method of increasing the bioavailability of glycopyrrolate by administration of a therapeutically effective amount of glycopyrrolate without food.
Patent expiration dates:
- April 24, 2024
  ✓
  Patent use: FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PEPTIC ULCER

Has a generic version of Striant been approved?

No. There is currently no therapeutically equivalent version of Striant available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Striant. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Bioadhesive progressive hydration tablets and methods of making and using the same
Patent 6,248,358
Issued: June 19, 2001
Inventor(s): Bologna; William J. & Levine; Howard L. & Cartier; Philippe & de Ziegler; Dominique
Assignee(s): Columbia Laboratories, Inc.
A bioadhesive tablet wherein the active ingredient may be protected from water or the surrounding environment, thereby protecting it from metabolism or from other degradation caused by moisture, enzymes, or pH effects, and making it bioavailable only at a controlled rate. The active ingredient may be protected from moisture during the manufacturing process and more importantly may be protected from moisture and the immediate septic environment until after the patient has applied the tablet, and then only at a slow and controlled rate. It is by this process of progressive hydration that the active ingredient remains protected for many hours after administration. It is also by the process of progressive hydration that controlled and sustained release is achieved because only that part of the active ingredient that is the hydrated (aqueous) fraction of the tablet is available for absorption (bioavailable).
Patent expiration dates:
- August 23, 2019
  ✓
  Patent use: METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE

Has a generic version of Symbyax been approved?

No. There is currently no therapeutically equivalent version of Symbyax available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Symbyax. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

2-methyl-thieno-benzodiazepine
Patent 5,229,382
Issued: July 20, 1993
Inventor(s): Chakrabarti; Jiban K. & Hotten; Terrence M. & Tupper; David E.
Assignee(s): Lilly Industries Limited
2-Methyl-10-(4-methyl-1-piperazinyl)-4H-thieno-[2,3-b][1,5]benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders of the central nervous system. The compound has the following structure: ##STR1##
Patent expiration dates:
- October 23, 2011
  ✓
  Pediatric exclusivity

Method for treating pain
Patent 5,945,416
Issued: August 31, 1999
Inventor(s): Shannon; Harlan E. & Womer; Daniel E.
Assignee(s): Eli Lilly and Company
The present invention provides a method for treating pain using a composition comprising olanzapine and Drug Useful in the Treatment of Pain.
Patent expiration dates:
- March 24, 2017
  ✓
  Drug substance
  ✓
  Drug product
  ✓
  Sponsor has requested patent be delisted

Combination therapy for treatment of refractory depression
Patent 6,960,577
Issued: November 1, 2005
Inventor(s): Tollefson; Gary Dennis
Assignee(s): Eli Lilly and Company
Methods for treating a patient suffering from or susceptible to treatment resistant major depression comprising administering olanzapine and fluoxetine are disclosed.
Patent expiration dates:
- November 1, 2017
  ✓
  Patent use: SYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS

Related Exclusivities

Exclusivity expiration dates:
- March 19, 2012 - TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD)

Has a generic version of Isovue-300 been approved?

Yes. The following products are equivalent to Isovue-300:

IOPAMIDOL-300 (iopamidol injectable; injection)

Manufacturer: APP PHARMS

Approval date: April 2, 1997

Strength(s): 61% ^[AP]

SCANLUX-300 (iopamidol injectable; injection)

Manufacturer: SANOCHEMIA CORP USA

Approval date: June 18, 2010

Strength(s): 61% ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Isovue-300. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Isovue-300.

Has a generic version of Istodax been approved?

No. There is currently no therapeutically equivalent version of Istodax available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Istodax. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

FR901228 substance and preparation thereof
Patent 4,977,138
Issued: December 11, 1990
Inventor(s): Okuhara; Masakuni & Goto; Toshio & Hori; Yasuhiro & Fujita; Takashi & Ueda; Hirotsugu & Shigematsu; Nobuharu
Assignee(s): Fujisawa Pharmaceutical Co., Ltd.
The invention relates to a compound having antimicrobial and antitumor activity, the compound being designated FR901228 substance of the following formula: ##STR1##
Patent expiration dates:
- July 6, 2012
  ✓
  Drug substance
  ✓
  Drug product

Method of producing FR901228
Patent 7,608,280
Issued: October 27, 2009
Inventor(s): Ueda; Satoshi & Watamoto; Yoko & Tsuboi; Masaru & Kanda; Munekazu & Higaki; Tomoji & Matsuda; Mitsunori
Assignee(s): Astellas Pharma Inc.
Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion. Also provided are crystalline forms of FR901228, e.g., type A and type B crystalline forms of FR901228.
Patent expiration dates:
- August 22, 2021
  ✓
  Drug substance

Method of producing FR901228
Patent 7,611,724
Issued: November 3, 2009
Inventor(s): Ueda; Satoshi & Watamoto; Yoko & Tsuboi; Masaru & Kanda; Munekazu & Higaki; Tomoji & Matsuda; Mitsunori
Assignee(s): Astellas Pharma Inc.
Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion. Also provided are crystalline forms of FR901228, e.g., type A and type B crystalline forms of FR901228.
Patent expiration dates:
- August 22, 2021
  ✓
  Drug substance

Related Exclusivities

Exclusivity expiration dates:
- November 5, 2014 - NEW CHEMICAL ENTITY
- November 5, 2016 - ORPHAN DRUG EXCLUSIVITY
- June 16, 2018 - ORPHAN DRUG EXCLUSIVITY

Has a generic version of Tensilon been approved?

Yes. The following products are equivalent to Tensilon:

ENLON (edrophonium chloride injectable; injection)

Manufacturer: BIONICHE PHARMA

Approval date: August 6, 1985

Strength(s): 10MG/ML ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tensilon. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Tensilon.

Has a generic version of Benzaclin been approved?

Yes. The following products are equivalent to Benzaclin:

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE (benzoyl peroxide; clindamycin phosphate gel; topical)

Manufacturer: DOW PHARM SCIENCES

Approval date: August 11, 2009

Strength(s): 5%;EQ 1% BASE ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Benzaclin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Benzaclin.

Has a generic version of Norvir been approved?

No. There is currently no therapeutically equivalent version of Norvir available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Norvir. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Pharmaceutical composition for inhibiting HIV protease
Patent 5,484,801
Issued: January 16, 1996
Inventor(s): Al-Razzak; Laman A. & Marsh; Kennan C. & Manning; Lourdes P. & Kaul; Dilip
Assignee(s): Abbott Laboratories
A pharmaceutical composition is disclosed which comprises a solution of an HIV protease inhibiting compound in a pharmaceutically acceptable organic solvent comprising a mixture of (1) (a) a solvent selected from propylene glycol and polyethylene glycol or (b) a solvent selected from polyoxyethyleneglycerol triricinoleate, polyethylene glycol 40 hydrogenated castor oil, fractionated coconut oil, polyoxyethylene (20) sorbitan monooleate and 2-(2-ethoxyethoxy)ethanol or (c) a mixture thereof and (2) ethanol or propylene glycol.
Patent expiration dates:
- January 28, 2014
- July 28, 2014
  ✓
  Pediatric exclusivity

Retroviral protease inhibiting compounds
Patent 5,541,206
Issued: July 30, 1996
Inventor(s): Kempf; Dale J. & Norbeck; Daniel W. & Sham; Hing Leung & Zhao; Chen
Assignee(s): Abbott Laboratories
A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed.
Patent expiration dates:
- July 30, 2013
  ✓
  Patent use: USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION
- July 30, 2013
  ✓
  Patent use: METHOD OF USE FOR INHIBITING HIV INFECTION
- July 30, 2013
  ✓
  Patent use: TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
  ✓
  Drug substance
  ✓
  Drug product
- January 30, 2014
  ✓
  Pediatric exclusivity

Retroviral protease inhibiting compounds
Patent 5,635,523
Issued: June 3, 1997
Inventor(s): Kempf; Dale J. & Norbeck; Daniel W. & Sham; Hing Leung & Zhao; Chen
Assignee(s): Abbott Laboratories
A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed.
Patent expiration dates:
- July 30, 2013
  ✓
  Patent use: USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR
- June 3, 2014
  ✓
  Patent use: USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR
- July 30, 2013
  ✓
  Patent use: METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS
- July 30, 2013
  ✓
  Patent use: TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
- January 30, 2014
  ✓
  Pediatric exclusivity
- December 3, 2014
  ✓
  Pediatric exclusivity

Retroviral protease inhibiting compounds
Patent 5,648,497
Issued: July 15, 1997
Inventor(s): Kempf; Dale J. & Norbeck; Daniel W. & Codacovi; Lynn M. & Sham; Hing L. & Wittenberger; Steven J.
Assignee(s): Abbott Laboraotries
A retroviral protease inhibiting compound of the formula A--X--B is disclosed. Also disclosed are a composition and method for inhibiting a retroviral protease and for treating an HIV infection. Also disclosed are processes and intermediates useful for the preparation of the retroviral protease inhibitors.
Patent expiration dates:
- July 15, 2014
- July 15, 2014
  ✓
  Drug substance
- January 15, 2015
  ✓
  Pediatric exclusivity

Retroviral protease inhibiting compounds
Patent 5,674,882
Issued: October 7, 1997
Inventor(s): Kempf; Dale J. & Norbeck; Daniel W. & Sham; Hing Leung & Zhao; Chen
Assignee(s): Abbott Laboratories
A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed.
Patent expiration dates:
- July 30, 2013
  ✓
  Patent use: TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
- July 30, 2013
  ✓
  Patent use: TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
- January 30, 2014
  ✓
  Pediatric exclusivity

Pharmaceutical composition
Patent 5,948,436
Issued: September 7, 1999
Inventor(s): Al-Razzak; Laman A. & Marsh; Kennan C. & Kaul; Dilip & Manning; Lourdes P.
Assignee(s): Abbott Laboratories
A pharmaceutical composition is disclosed which comprises a solution of an HIV protease inhibiting compound in a pharmaceutically acceptable organic solvent comprising a pharmaceutically acceptable alcohol. The composition can optionally comprise a pharmaceutically acceptable acid or a combination of pharmaceutically acceptable acids. The solution can optionally be encapsulated in hard gelatin capsules or soft elastic gelatin capsules. The solution can optionally be granulated with a pharmaceutically acceptable granulating agent.
Patent expiration dates:
- September 13, 2013
  ✓
  Drug product
- September 13, 2013
- March 13, 2014
  ✓
  Pediatric exclusivity

Method for improving pharmacokinetics
Patent 6,037,157
Issued: March 14, 2000
Inventor(s): Norbeck; Daniel W. & Kempf; Dale J. & Leonard; John M. & Bertz; Richard J.
Assignee(s): Abbott Laboratories
A method is disclosed for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase.
Patent expiration dates:
- June 26, 2016
- June 26, 2016
  ✓
  Patent use: TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
- June 26, 2016
  ✓
  Patent use: TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
- December 26, 2016
  ✓
  Pediatric exclusivity

Pharmaceutical composition
Patent 6,232,333
Issued: May 15, 2001
Inventor(s): Lipari; John & Al-Razzak; Laman A. & Ghosh; Soumojeet & Gao; Rong & Kaul; Dilip
Assignee(s): Abbott Laboratories
A liquid pharmaceutical composition providing improved oral bioavailability is disclosed for compounds which are inhibitors of HIV protease. In particular, the composition comprises a solution in a pharmaceutically acceptable organic solvent of (a) the HIV protease inhibitor and, optionally, (b) a surfactant. The composition can optionally be encapsulated in either hard gelatin capsules or soft elastic capsules (SEC).
Patent expiration dates:
- November 7, 2017
- May 7, 2018
  ✓
  Pediatric exclusivity

Method for improving pharmacokinetics
Patent 6,703,403
Issued: March 9, 2004
Inventor(s): Daniel W.; Norbeck & Dale J.; Kempf & John M.; Leonard & Richard J.; Bertz
Assignee(s): Abbott Laboratories
A method is disclosed for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase.
Patent expiration dates:
- June 26, 2016
  ✓
  Patent use: TREATMENT OF HIV IN CONCOMITANT THERAPY
- June 26, 2016
  ✓
  Patent use: TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
- December 26, 2016
  ✓
  Pediatric exclusivity

Pharmaceutical formulations
Patent 7,141,593
Issued: November 28, 2006
Inventor(s): Alani; Laman & Ghosh; Soumojeet
Assignee(s): Abbott Laboratories
Improved pharmaceutical compositions are provided comprising one or more solubilized HIV protease inhibiting compounds having improved solubility properties in a medium and/or long chain fatty acid, or mixtures thereof, a pharmaceutically acceptable alcohol, and water.
Patent expiration dates:
- May 22, 2020
  ✓
  Drug product
- November 22, 2020
  ✓
  Pediatric exclusivity

Polymorph of a pharmaceutical
Patent 7,148,359
Issued: December 12, 2006
Inventor(s): Chemburkar; Sanjay R. & Patel; Ketan
Assignee(s): Abbott Laboratories
A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed.
Patent expiration dates:
- July 19, 2019
  ✓
  Drug product
- January 19, 2020
  ✓
  Pediatric exclusivity

Solid dispersion pharamaceutical formulations
Patent 7,364,752
Issued: April 29, 2008
Inventor(s): Fort; James J. & Krill; Steven L. & Law; Devalina & Qiu; Yihong & Porter; William R. & Schmitt; Eric A.
Assignee(s): Abbott Laboratories
A pharmaceutical composition is disclosed which comprises a solid dispersion of an HIV protease inhibitor in a water soluble carrier, such as PEG, having enhanced bioavailability and improved dissolution properties. The solid dispersion may optionally be encapsulated in hard gelatin capsules, compressed into a tablet, or may be granulated with a pharmaceutically acceptable granulating agent. Also disclosed are methods of making said solid dispersion and methods of treating an HIV infection employing said solid dispersion.
Patent expiration dates:
- November 10, 2020
  ✓
  Patent use: TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
  ✓
  Drug product
- May 10, 2021
  ✓
  Pediatric exclusivity

Pharmaceutical formulations
Patent 7,432,294
Issued: October 7, 2008
Inventor(s): Alani; Laman & Ghosh; Soumojeet
Assignee(s): Abbott Laboratories
Improved pharmaceutical compositions are provided comprising one or more solubilized HIV protease inhibiting compounds having improved solubility properties in a medium and/or long chain fatty acid, or mixtures thereof, a pharmaceutically acceptable alcohol, and water.
Patent expiration dates:
- May 22, 2020
  ✓
  Drug product
- November 22, 2020
  ✓
  Pediatric exclusivity

Has a generic version of Periostat been approved?

Yes. The following products are equivalent to Periostat:

doxycycline hyclate tablet; oral

Manufacturer: COREPHARMA

Approval date: May 13, 2005

Strength(s): EQ 20MG BASE ^[AB]

Manufacturer: IVAX SUB TEVA PHARMS

Approval date: May 13, 2005

Strength(s): EQ 20MG BASE ^[AB]

Manufacturer: LANNETT

Approval date: November 10, 2005

Strength(s): EQ 20MG BASE ^[AB]

Manufacturer: MUTUAL PHARMA

Approval date: May 13, 2005

Strength(s): EQ 20MG BASE ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Periostat. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Periostat.

Has a generic version of Docefrez been approved?

No. There is currently no therapeutically equivalent version of Docefrez available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Docefrez. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Docefrez.

Has a generic version of Zmax been approved?

No. There is currently no therapeutically equivalent version of Zmax available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zmax. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Controlled-release dosage forms of Azithromycin
Patent 6,068,859
Issued: May 30, 2000
Inventor(s): Curatolo; William J. & Friedman; Hylar L. & Korsmeyer; Richard W. & LeMott; Steven R.
Assignee(s): Pfizer Inc.
A controlled-release dosage form of azithromycin having an improved side effect profile; a process for preparing the dosage form; and a method of treating a microbial infection, comprising administering azithromycin in such a controlled-release dosage form to a mammal, including a human patient, in need of such treatment.
Patent expiration dates:
- May 30, 2017
  ✓
  Drug product

Azithromycin dihydrate
Patent 6,268,489
Issued: July 31, 2001
Inventor(s): Allen; Douglas J. M. & Nepveux; Kevin M.
Assignee(s): Pfizer Inc.
Non-hygroscopic, azithromycin (9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin) dihydrate and a process therefor.
Patent expiration dates:
- July 31, 2018
  ✓
  Drug substance

Azithromycin dosage forms with reduced side effects
Patent 6,984,403
Issued: January 10, 2006
Inventor(s): Hagen; Timothy A. & Lo; Julian B. & Thombre; Avinash G. & Herbig; Scott M. & Appel; Leah Elizabeth & Crew; Marshall David & Friesen; Dwayne Thomas & Lyon; David Keith & McCray; Scott Baldwin & West; James Blair
Assignee(s): Pfizer Inc.
The present invention is related to an oral dosage form comprising an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a glyceride which comprises glyceryl monobehenate, glyceryl dibehenate, glyceryl tribehenate, or a mixture thereof and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule.
Patent expiration dates:
- February 14, 2024
  ✓
  Patent use: METHOD OF TREATING BACTERIAL INFECTIONS
  ✓
  Drug product

Multiparticulate crystalline drug compositions having controlled release profiles
Patent 7,887,844
Issued: February 15, 2011
Inventor(s): Appel; Leah E. & Ray; Roderick J. & Lyon; David K. & West; James B. & McCray; Scott B. & Crew; Marshall D. & Friesen; Dwayne T. & Herbig; Scott M. & Lo; Julian B.
Assignee(s): Pfizer Inc.
A multiparticulate for controlled release of a drug comprises crystalline drug, a glyceride having at least one alkylate substituent of at least 16 carbon atoms, and a poloxamer, wherein at least 70 wt % of the drug in the multiparticulate is crystalline.
Patent expiration dates:
- February 14, 2024
  ✓
  Drug product

Has a generic version of Corlopam been approved?

Yes. The following products are equivalent to Corlopam:

fenoldopam mesylate injectable; injection

Manufacturer: BEDFORD LABS

Approval date: October 12, 2004

Strength(s): EQ 10MG BASE/ML ^[AP]

Manufacturer: SANDOZ

Approval date: February 15, 2005

Strength(s): EQ 10MG BASE/ML ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Corlopam. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Corlopam.

Has a generic version of Cosmegen been approved?

Yes. The following products are equivalent to Cosmegen:

dactinomycin injectable; injection

Manufacturer: BEDFORD

Approval date: March 16, 2010

Strength(s): 0.5MG/VIAL ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cosmegen. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Cosmegen.

Has a generic version of Crestor been approved?

No. There is currently no therapeutically equivalent version of Crestor available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Crestor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Pharmaceutical compositions
Patent 6,316,460
Issued: November 13, 2001
Inventor(s): Creekmore; Joseph R & Wiggins; Norman A.
Assignee(s): Astrazeneca AB
The invention concerns a pharmaceutical composition comprising the HMG CoA reductase inhibitor (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrim idin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof as the active ingredient, which remains stable over a prolonged period.
Patent expiration dates:
- August 4, 2020
  ✓
  Drug product
- February 4, 2021
  ✓
  Pediatric exclusivity

Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia
Patent 6,858,618
Issued: February 22, 2005
Inventor(s): Raza; Ali & Hutchinson; Howard Gerard
Assignee(s): AstraZeneca AB
The invention provides a method for the treatment of heterozygous familial hypercholesterolemia by administering the compound (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof.
Patent expiration dates:
- December 17, 2021
  ✓
  Patent use: USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB, NONHDL-C OR TG LEVELS; TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA; AND TO SLOW THE PROGRESSION OF ATHEROSCLEROSIS.
- June 17, 2022
  ✓
  Pediatric exclusivity

Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
Patent 7,030,152
Issued: April 18, 2006
Inventor(s): Ridker; Paul & Hennekens; Charles H.
Assignee(s): The Brigham and Women's Hospital, Inc.
The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder by obtaining a level of the marker of systemic inflammation in the individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorder.
Patent expiration dates:
- April 2, 2018
  ✓
  Patent use: USE OF ROSUVASTATIN CALCIUM FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN INDIVIDUALS WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH INCREASED RISK FACTORS
- October 2, 2018
  ✓
  Pediatric exclusivity

Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
Patent 7,964,614
Issued: June 21, 2011
Inventor(s): Ridker; Paul & Hennekens; Charles H.
Assignee(s): The Brigham and Women's Hospital, Inc.
The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder by obtaining a level of the marker of systemic inflammation in the individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorder.
Patent expiration dates:
- April 2, 2018
  ✓
  Patent use: USE OF ROSUVASTATIN CALCIUM FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN INDIVIDUALS WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH INCREASED RISK FACTORS
- October 2, 2018
  ✓
  Pediatric exclusivity

Pyrimidine derivatives
Patent RE37314
Issued: August 7, 2001
Inventor(s): Hirai; Kentaro & Ishiba; Teruyuki & Koike; Haruo & Watanabe; Masamichi
Assignee(s): Shionogi Seiyaku Kabushiki Kaisha
The compounds of the present invention inhibit the HMG-CoA reductase, and subsequently suppress the biosynthesis of cholesterol. And they are useful in the treatment of hypercholesterolemia, hyperlipoproteinemia, and atherosclerosis.
Patent expiration dates:
- January 8, 2016
  ✓
  Drug substance
- July 8, 2016
  ✓
  Pediatric exclusivity

Related Exclusivities

Exclusivity expiration dates:
- November 8, 2010 - ADJUNCTIVE THERAPY TO DIET TO SLOW THE PROGRESSION OF ARTHEROSCLEROSIS IN ADULT PATIENTS AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL-C AND LDL-C TO TARGET LEVELS
- May 8, 2011 - PEDIATRIC EXCLUSIVITY
- November 6, 2011 - TO TREAT PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDICKSON TYPE III HYPERLIPOPROTEINEMIA) AS AN ADJUNCT TO DIET
- May 6, 2012 - PEDIATRIC EXCLUSIVITY
- October 16, 2012 - TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND POSTMENARCHAL GIRLS, AGES 10 TO 17 YEARS, WITH A RECOMMENDATION DOSING RANGE OF 5 TO 20 MG ONCE DAILY
- February 8, 2013 - PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, BASED ON THE RESULTS OF JUSTIFICATION FOR THE USE OF STATINS IN PRIMARY PREVENTION; AN INTERVENTION TRIAL EVALUATING ROSUVASTATIN (JUPITER)
- April 16, 2013 - PEDIATRIC EXCLUSIVITY

Wednesday, October 12, 2016

METROGEL (metronidazole - gel; topical)

Has a generic version of MetroGel been approved?

metronidazole gel; topical

Related Patents

See also...

MIFEPREX (mifepristone - tablet; oral)

Has a generic version of Mifeprex been approved?

Related Patents

See also...

DUODOTE (atropine; pralidoxime chloride - injectable; intramuscular)

Has a generic version of DuoDote been approved?

Related Patents

See also...

CAPASTAT SULFATE (capreomycin sulfate - injectable; injection)

Has a generic version of Capastat Sulfate been approved?

Related Patents

See also...

CARAFATE (sucralfate - suspension; oral)

CARAFATE (sucralfate - tablet; oral)

Has a generic version of Carafate been approved?

sucralfate tablet; oral

Related Patents

See also...

SOMAVERT (pegvisomant - injectable; subcutaneous)

Has a generic version of Somavert been approved?

Related Patents

See also...

BREVIBLOC (esmolol hydrochloride - injectable; injection)

Has a generic version of Brevibloc been approved?

esmolol hydrochloride injectable; injection

Related Patents

See also...

CIPRO HC (ciprofloxacin hydrochloride; hydrocortisone - suspension/drops; otic)

Has a generic version of Cipro HC been approved?

Related Patents

See also...

AVODART (dutasteride - capsule; oral)

Has a generic version of Avodart been approved?

dutasteride capsule; oral

Related Patents

Related Exclusivities

See also...

ROBINUL (glycopyrrolate - injectable; injection)

ROBINUL (glycopyrrolate - tablet; oral)

Has a generic version of Robinul been approved?

glycopyrrolate injectable; injection

glycopyrrolate tablet; oral

Related Patents

See also...

STRIANT (testosterone - tablet, extended release; buccal)

Has a generic version of Striant been approved?

Related Patents

See also...

SYMBYAX (fluoxetine hydrochloride; olanzapine - capsule; oral)

Has a generic version of Symbyax been approved?

Related Patents

Related Exclusivities

See also...

ISOVUE-300 (iopamidol - injectable; injection)

Has a generic version of Isovue-300 been approved?

IOPAMIDOL-300 (iopamidol injectable; injection)

SCANLUX-300 (iopamidol injectable; injection)

Related Patents

See also...

ISTODAX (romidepsin - powder; iv (infusion))

Has a generic version of Istodax been approved?

Related Patents

Related Exclusivities

See also...

TENSILON (edrophonium chloride - injectable; injection)

Has a generic version of Tensilon been approved?

ENLON (edrophonium chloride injectable; injection)

Related Patents

See also...

BENZACLIN (benzoyl peroxide; clindamycin phosphate - gel; topical)

Has a generic version of Benzaclin been approved?

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE (benzoyl peroxide; clindamycin phosphate gel; topical)

Related Patents

See also...